RUTH MATTHEW R. (Chief Commercial Officer) received a stock award from OPIANT PHARMACEUTICALS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 3/3/2023ACC: 0001385508-23-000073
Officer· Chief Commercial Officer
Since Jul 2021
-79.92K
Net shares
Net seller
$638.3K
Total sold
0
Open market trades
0B · 0S
5
Total transactions
2K acquired · 81.92K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−19.25K
Price / share
$20.00
Trade value
$385K
% of position
64.3%
3/2/2023
29.92K→10.67K
Common Stock
Direct
Shares
−10.67K
Price / share
$20.00
Trade value
$213.32K
% of position
New position
3/2/2023
10.67K→0.00
Common Stock
Direct
Shares
+2K
Price / share
—
Trade value
—
% of position
New position
3/2/2023
0.00→2K
Common Stock
Direct
Shares
−2K
Price / share
$20.00
Trade value
$40K
% of position
New position
3/2/2023
2K→0.00
Total
Net shares
−29.92K
Net value
-$638.32K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/2/2023 | D · Disposition | −19.25K | $20.00 | $385K | 64.3% | 29.92K | 10.67K |
| Common Stock Direct | 3/2/2023 | D · Disposition | −10.67K | $20.00 | $213.32K | New position | 10.67K | 0.00 |
| Common Stock Direct | 3/2/2023 | A · Award | +2K | — | — | New position | 0.00 | 2K |
| Common Stock Direct | 3/2/2023 | D · Disposition | −2K | $20.00 | $40K | New position | 2K | 0.00 |
| Total | −29.92K | -$638.32K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
50K shares
Shares
−50K
Strike price
16.41
Held after
0.00
Exercisable
—
3/2/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock50K shares | 3/2/2023 | D · Disposition | −50K | 16.41 | — | 0.00 |